Verona Pharma Stock Soars 19.73% on Merck Acquisition Rumors

On July 9, 2025, Verona Pharma's stock surged by 19.73% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Verona Pharma's stock price has seen a notable increase following reports that Merck is nearing a $10 billion deal to acquire the respiratory drugmaker. This potential acquisition has sparked optimism among investors, as it represents a significant premium over Verona Pharma's previous closing price. The deal, if finalized, would see Merck pay $107 per American depository share, reflecting a 23% premium to Verona Pharma's stock price on Tuesday. This acquisition would allow Merck to expand its portfolio in the respiratory disease sector, leveraging Verona Pharma's expertise and innovative treatments.